Trials / Completed
CompletedNCT04470544
Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19
RECOVER: Phase 2 Randomized, Double-Blind Trial TREating Hospitalized Patients With COVID-19 With Camostat MesilatE, a TMPRSS2 Inhibitor
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Alan Bryce · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine if the reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with standard of care (SOC) treatment will increase the proportion of patients alive and free from respiratory failure at Day 28 in SARS-CoV-2 as compared to SOC treatment with placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camostat Mesilate | Given PO |
| OTHER | Standard of Care | At Investigator discretion |
Timeline
- Start date
- 2020-07-28
- Primary completion
- 2021-12-22
- Completion
- 2022-01-20
- First posted
- 2020-07-14
- Last updated
- 2024-11-12
- Results posted
- 2024-11-12
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04470544. Inclusion in this directory is not an endorsement.